• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dexcom wins FDA breakthrough nod for use of its CGM in hospitals

March 2, 2022 By Sean Whooley

Dexcom updated logoDexcom (NSDQ:DXCM) announced that it received FDA breakthrough device designation for the use of its CGM in a hospital setting.

The FDA early in the COVID-19 pandemic issued temporary guidance allowing increased remote monitoring of hospital patients in order to limit contact with hospital staff. The guidance included continuous glucose monitors.

“What started as a response during the pandemic has shown promise as a better alternative to fingerstick blood glucose tests with greater quality of care and patient satisfaction,” Dexcom VP and GM of Hospitals Gil Rivas said in a news release.

Dexcom CEO Kevin Sayer has said in the past that he sees hospital settings as an additional market for CGMs.

The Dexcom continuous glucose monitor uses a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a smart device to provide real-time glucose data and eliminate the need for fingersticks. It also offers customizable alerts and alarms to make the patient aware of blood sugar levels and potentially avoid dangerous low and high blood sugar events.

Scripps Whittier Diabetes Institute Corporate VP Dr. Athena Philis-Tsimikas said that San Diego-based Dexcom’s CGM has been used in hospitals as part of exploratory studies over the last seven years.

In those exploratory studies, with more than 800 patients involved treated during the COVID-19 pandemic, Philis-Tsimikas said the device was found to have improved glucose control without any increased risk of hypoglycemia. She called breakthrough designation potentially “transformative for using CGM for in-patient care in hospitals.”

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Hospital Care, Patient Monitoring Tagged With: Dexcom, FDA

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS